Robles BioCeutics, a regenerative dermatology company focused on translating senolytic science and stem cell–inspired research into next-generation skincare, has announced the publication of its first peer-reviewed scientific paper in The Journal of Translational Medicine. The study, titled “Unleashing Endogenous Regeneration by Senolytics,” marks a significant milestone for the company and strengthens the scientific credibility of its proprietary platform.
The publication represents a key step in validating Robles BioCeutics’ approach to skin regeneration, helping to de-risk its technology while reinforcing the research foundation behind its product development strategy. The paper explores how targeting senescent cells—aged or dysfunctional cells that accumulate over time—can enhance the body’s natural regenerative pathways.
According to the study, integrating senolytic mechanisms with stem cell–inspired signaling may support more effective skin repair and renewal. This dual-action strategy underpins the company’s broader regenerative skincare platform and directly informs the development of GlowSelle™, Robles BioCeutics’ patent-pending formulation designed to promote skin health, resilience, and long-term renewal.
Dr. Santosh Kesari, founder and medical doctor at Asthra Health and a contributor to the research, emphasized the significance of the approach. “While much of the beauty and dermatology industry focuses solely on stimulating regeneration, this work addresses an equally important factor—reducing senescent cells that can block the body’s natural repair processes,” he said. “Tackling both aspects of aging simultaneously is a powerful strategy, and Robles BioCeutics is helping define a new direction for regenerative skin solutions.”
Maria Robles, CEO and President of Robles BioCeutics, described the publication as a pivotal moment for the company. “Seeing our work published in The Journal of Translational Medicine is an incredible honor,” she said. “This milestone is more than academic recognition—it validates the science we have spent years building and confirms our belief in where regenerative dermatology must go. By combining senolytics with stem cell–inspired biology, we aim to create meaningful advances in skin health and aging.”
Robles BioCeutics was founded with the goal of addressing unmet needs in dermatology through clinically inspired, science-driven innovation. The company’s pipeline focuses on targeting the biological drivers of skin aging, repair, and longevity, with an emphasis on translating rigorous research into practical skincare applications.
